HIV/AIDS

The risk of acute coronary syndrome recurring after hospitalization was not found to be increased in individuals infected with HIV.

Investigators found associations between ART and ISTI-based regimens and increased viral suppression rates across the United States.

DELSTRIGO and PIFELTRO have been indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience.

Results of an analysis indicate suicidal behavior occurred more often in patients taking an efavirenz-based treatment for HIV than in a control group that had not started treatment.

The first darunavir-based single tablet regimen for HIV has shown positive results in trials as both a switch therapy and for the rapid initiation of treatment in those who are newly diagnosed.

Phase 3 data for ibalizumab showed that nearly half of patients had a reduction in viral load of more than 80% after 25 weeks of therapy.

A review of the research on eHealth and mHealth interventions for youth with HIV concludes these types of interventions should be scaled up and more widely implemented.

Participants in the Project LifeSkills intervention had a 39.8% greater mean reduction in condomless sex compared to participants receiving standard care.

A retrospective study showed a probability of maintaining HIV viral suppression of 98.2% at 48 weeks and 95.1% at 96 weeks, with the switch to the dolutegravir/lamivudine antiretroviral regimen.

Two studies examine whether users of daily oral PrEP would switch to a long-acting injection with interesting results.

Merck’s new non-nucleoside reverse transcriptase inhibitor (NNRTI), doravirine, achieved viral suppression in 73.1% of patients, according to new data released by the company.

Overweight and obesity in people with HIV are linked to behavioral factors and longer lives, not adverse effects of antiretroviral therapy, according to a new study.

A new company says urine tests can help physicians determine whether a patient at risk of HIV infection is adhering to their pre-exposure prophylaxis regimen.

At the 100-week mark, 89% of participants taking dolutegravir/rilpivirine (Juluca) maintained viral suppression, with viral loads of < 50 copies/mL.

Researchers found that just 18.4% of young women diagnosed at pediatric emergency departments with pelvic inflammatory disease received HIV and syphilis screening, despite their higher risk for those sexually transmitted infections.

Among men who have sex with men, the increased odds of a new HIV infection per HIV-positive partner was reduced by 91% for each partner with whom condoms were always used.

SYMTUZA has been approved by the FDA based on the data of a pair of 48-week pivotal phase 3 trials which showed the non-inferiority safety and efficacy of the drug versus a controlled regimen.

The CDC finds that substantial numbers of persons unaware of their HIV infection report missed opportunities for earlier diagnosis.

An online prevention program that uses a soap opera format was shown to be effective at lowering rates of STIs.

First-line protease inhibitors posed different risks for cardiovascular disease in an international study of adverse events in HIV patients.

A modelling study showed that injectable PrEP could be more effective at reducing HIV transmission than oral PrEP.

New research suggests cirrhosis, not HCV status, is the reason diabetes rates are higher among HCV-infected patients.

Reports published by the CDC indicate that HIV screening is underutilized, and that providers often do not offer the test to patients who could benefit.

New research finds patients with HIV and chronic pain are aware that opioids are addictive, yet most don’t receive common addiction-prevention monitoring.

Sterile syringe access as part of comprehensive HIV prevention is important to control and prevent outbreaks.

New research from the University of Virginia shows that a smartphone app can make a major impact on the health of people living with HIV.

Just 12% of the US population, African-Americans account for nearly 50% of the HIV/AIDS cases in the country.

Eligibility criteria for HIV pre-exposure prophylaxis (PrEP) based on behavioral markers does not capture all with biological markers for HIV risk.

HIV-positive patients who take antiretroviral therapy have a lower risk of cancer than HIV-positive patients who are not taking antiretroviral drugs.

A new Australian study found overall condom use decreased when PrEP was introduced into the region.